Roivant Sciences CEO Sells $8.45 Million in Shares Near 52-Week High
ROIV has more than doubled off its 52-week low of $10.01.
Summary
Matthew Gline, CEO of Roivant Sciences, disposed of over $8.4 million worth of common shares in an open market transaction.
Key Events · Ownership and Investor Activity · ROIV
-
CEO Sells Significant Stake
Matthew Gline, CEO and Director, sold 289,774 common shares in an open market transaction.
-
$8.45 Million Share Disposition
The total value of the shares sold amounted to approximately $8,449,810.
-
Sale Near 52-Week High
The shares were sold at a weighted average price of $29.16, close to the company's 52-week high of $30.33.
Analysis · ROIV · Life Sciences
This Form 4 filing reports a significant open market sale by CEO Matthew Gline, disposing of 289,774 shares for approximately $8.45 million. The sale occurred at a weighted average price of $29.16 per share, close to the company's 52-week high. While the transaction represents a small percentage of the company's large market capitalization, a multi-million dollar sale by the chief executive can be interpreted as a signal, especially when the stock is trading at elevated levels. Investors may view this as the CEO taking profits.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $29.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8B. The 52-week trading range was $10.01 to $30.33. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.